News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
333,266 Results
Type
Article (15984)
Company Profile (30)
Press Release (317252)
Section
Business (109891)
Career Advice (927)
Deals (20277)
Drug Delivery (33)
Drug Development (39804)
Employer Resources (81)
FDA (7035)
Job Trends (6785)
News (177990)
Policy (13471)
Tag
Academia (1237)
Africa (367)
Alabama (14)
Allergies (15)
Alliances (23877)
Alzheimer's disease (481)
Antibody-drug conjugate (ADC) (14)
Approvals (7014)
Arizona (51)
Artificial intelligence (17)
Asia (19495)
Australia (3225)
Bankruptcy (143)
Best Places to Work (5140)
Biosimilars (20)
C2C Services and Suppliers (37155)
California (372)
Canada (305)
Cancer (67)
Career advice (778)
Cell therapy (28)
China (22)
Clinical research (32014)
Collaboration (20)
Colorado (16)
COVID-19 (1210)
Cystic fibrosis (18)
Delaware (12)
Diagnostics (2979)
Diversity, equity & inclusion (28)
Drug pricing (22)
Earnings (45168)
Employer resources (72)
Europe (46411)
Events (50258)
Executive appointments (15)
FDA (7050)
Florida (42)
Funding (19)
Gene therapy (23)
Georgia (15)
GLP-1 (228)
Government (1404)
Healthcare (9019)
Hotbed/Location (231734)
Idaho (36)
Illinois (95)
Indiana (42)
Infectious disease (1213)
Inflammatory bowel disease (41)
Interviews (140)
IPO (9379)
Job creations (1667)
Job search strategy (707)
Kansas (44)
Layoffs (139)
Legal (3413)
Liver cancer (26)
Lung cancer (13)
Maine (38)
Management (25)
Manufacturing (17)
Maryland (103)
Massachusetts (234)
Medical device (5950)
Medtech (5951)
Mergers & acquisitions (10780)
Metabolic disorders (55)
Neuroscience (511)
New Jersey (31)
New York (38)
NextGen Class of 2024 (3136)
Non-profit (2055)
North Carolina (61)
Obesity (41)
Opinion (54)
Parkinson's disease (13)
Peanut (15)
Pennsylvania (23)
People (33194)
Phase I (8348)
Phase II (13844)
Phase III (12052)
Policy (15)
Postmarket research (1454)
Preclinical (3231)
Rare diseases (29)
Real estate (2845)
Recruiting (25)
Regulatory (8931)
Reports (19)
Research institute (1078)
Resumes & cover letters (131)
South America (561)
Startups (1812)
Texas (36)
United States (1359)
Vaccines (194)
Washington State (37)
Weight loss (31)
Date
Today (21)
Last 7 days (232)
Last 30 days (864)
Last 365 days (18408)
2024 (10321)
2023 (19730)
2022 (26883)
2021 (29263)
2020 (27615)
2019 (22963)
2018 (17539)
2017 (16659)
2016 (15808)
2015 (19574)
2014 (14657)
2013 (11771)
2012 (12602)
2011 (13407)
2010 (12506)
333,266 Results for "sosei group corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
Sosei Group Corporation, announces that at a meeting held on 15 February 2024, its Board of Directors resolved to change the corporate names of the Company and its subsidiaries and the location of the head office of the Company.
February 15, 2024
·
6 min read
Business
Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer
Sosei Group Corporation announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer.
January 5, 2024
·
4 min read
Business
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
Boehringer Ingelheim and Sosei Group Corporation announced they have entered a global collaboration and exclusive option-to-license agreement.
March 11, 2024
·
10 min read
Business
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
Sosei Group Corporation announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.
March 27, 2024
·
4 min read
Genetown
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
February 13, 2024
·
10 min read
Policy
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
Sosei Group Corporation announces that PIVLAZ™ 150 mg has received marketing approval from the Ministry of Food and Drug Safety in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing.
December 7, 2023
·
8 min read
Genetown
Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
Sosei Group Corporation announces that Formosa Pharmaceuticals, Inc. has received approval from the US Food & Drug Administration for clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery.
March 6, 2024
·
3 min read
Genetown
Sosei Heptares Webinar Presentation for FY2023 Financial Results
Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024.
January 22, 2024
·
2 min read
Genetown
Nxera Pharma is the New Name for Sosei Group
Nxera Pharma Co., Ltd. is pleased to announce the launch of its new company name, having received approval at the 34th Ordinary General Meeting of Shareholders held on 27 March 2024.
March 31, 2024
·
4 min read
Genetown
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
Sosei Group Corporation announces it has regained full ownership from GSK of HTL0027477, a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for Inflammatory Bowel Diseases.
March 20, 2024
·
4 min read
1 of 33,327
Next
